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Introduction: Duchenne muscular dystrophy (DMD), caused by a lack of the functional structural protein
dystrophin, leads to severe muscle degeneration where the patients are typically wheelchair-bound and die in their
mid-twenties from cardiac or respiratory failure or both. The aim of this study was to investigate the potential of
human dental pulp stem cells (hDPSCs) and human amniotic fluid stem cells (hAFSCs) to differentiate toward a
skeletal myogenic lineage using several different protocols in order to determine the optimal conditions for
achieving myogenic commitment and to subsequently evaluate their contribution in the improvement of the
pathological features associated with dystrophic skeletal muscle when intramuscularly injected into mdx/SCID mice,
an immune-compromised animal model of DMD.
Methods: Human DPSCs and AFSCs were differentiated toward myogenic lineage in vitro through the direct
co-culture with a myogenic cell line (C2C12 cells) and through a preliminary demethylation treatment with
5-Aza-2′-deoxycytidine (5-Aza), respectively. The commitment and differentiation of both hDPSCs and hAFSCs were
evaluated by immunofluorescence and Western blot analysis. Subsequently, hDPSCs and hAFSCs, preliminarily
demethylated and pre-differentiated toward a myogenic lineage for 2 weeks, were injected into the dystrophic
gastrocnemius muscles of mdx/SCID mice. After 1, 2, and 4 weeks, the gastrocnemius muscles were taken for
immunofluorescence and histological analyses.
Results: Both populations of cells engrafted within the host muscle of mdx/SCID mice and through a paracrine
effect promoted angiogenesis and reduced fibrosis, which eventually led to an improvement of the histopathology
of the dystrophic muscle.
Conclusion: This study shows that hAFSCs and hDPSCs represent potential sources of stem cells for translational
strategies to improve the histopathology and potentially alleviate the muscle weakness in patients with DMD.Introduction
Duchenne muscular dystrophy (DMD) is an X-linked re-
cessive genetic disease characterized by the lack of the
structural protein, dystrophin, which is the primary com-
ponent of the dystrophin-glycoprotein complex (DGC)
that links the cytoskeleton to the extracellular matrix, thus
providing stability to the sarcolemma during muscle con-
traction [1]. DMD is one of the most common (1 in 3500* Correspondence: jhuard@pitt.edu
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article, unless otherwise stated.live male births) and severe of the muscular dystrophies,
presenting with severe progressive degeneration of skeletal
muscle fibers and resulting in the death of the patients,
typically before their third decade of life [2].
The use of corticosteroids delays the loss of muscle
function in patients with DMD; however, currently no
therapy is capable of preventing the progressive muscle
degenerative processes associated with DMD [3], al-
though several different therapeutic approaches, in-
cluding cell and gene therapies, have been tested over
the years.
Cell therapy could be used to recover the lack of dys-
trophin in dystrophic muscles and thus repair theicle is distributed under the terms of the Creative Commons Attribution 4.0
ns.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
give appropriate credit to the original author(s) and the source, provide a
indicate if changes were made. The Creative Commons Public Domain
.org/publicdomain/zero/1.0/) applies to the data made available in this
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generation. Recently, various stem cell populations
have been used to treat muscular dystrophy. Although
dystrophin represents the major target protein to be
restored in patients with DMD, it has become clear
over the last few years that an improvement of muscle
histopathologies through promotion of angiogenesis
and reduction of fibrosis can be achieved via a para-
crine effect of the injected stem cells [4–6].
Stem cells obtained from different sources, including
bone marrow, adipose tissue, umbilical cord, and pla-
centa, have been investigated and could represent alter-
native tissue sources for obtaining adult multi-lineage
progenitor cells [7–10]. Human dental pulp stem cells
(hDPSCs) have been identified and can be harvested
from human dental pulp during routine extraction of ei-
ther deciduous teeth or third molars. hDPSCs have been
widely demonstrated to be clonogenic cells capable of
both self-renewal and multiple lineage differentiation
[11–13]. Human amniotic fluid stem cells (hAFSCs)
have also been identified and constitute approximately
1 % of the cells that could potentially be obtained from
human amniocentesis backup specimens [14], samples
that would otherwise be discarded. hAFSCs have been
shown to possess self-renewal and multi-differentiation
capacities, do not induce or form teratomas, and are far
less controversial than embryonic stem cells [14, 15].
In this study, we investigated the potential of hDPSCs
and hAFSCs to differentiate toward a skeletal myogenic
lineage by using several different protocols in order to
determine the optimal conditions for achieving myo-
genic commitment. The first protocol was based on the
direct co-culture of the human cells with murine myo-
blasts in order to evaluate the capacity of both popula-
tions to fuse and form mature myotubes when directly
co-cultured with mouse myoblasts.
The second protocol was based on the use of the
demethylating agent 5-Aza-2′-deoxycytidine (5-Aza) and
supplementation of the cultures with or without the
addition of conditioned medium (CM) from differenti-
ated mouse myoblast cultures, medium that contains
numerous soluble factors that can promote myogenic
differentiation, including insulin-like growth factor-II
(IGF-II) [16]. To verify the effective differentiation of the
hDPSCs and hAFSCs toward a skeletal myogenic lineage,
we investigated the expression of muscle-specific factors
and markers, including myogenin, myosin heavy chain
(MyHC), and desmin.
It has been previously established that genes related
to myogenic differentiation are controlled by DNA
methylation and that the use of the demethylating agent
5-Aza was able to induce adult human bone marrow
stem cells to differentiate toward a cardiomyogenic lineage
[17, 18]. Also, demethylating agent 5-Aza was found ableto increase the myogenic potential of muscle cells [19].
After treatment with 5-Aza and pre-differentiation
in vitro, we tested the ability of the hDPSCs and
hAFSCs to restore dystrophin expression and contribute
to the amelioration of the pathological features associated
with dystrophic skeletal muscle when intramuscularly
injected into mdx/SCID mice, an immune-compromised
animal model of DMD.
Methods
Cell culture and sorting
Human dental pulp was extracted from the enclosed
third molar of teenage subjects undergoing routine tooth
extractions, following written informed consent from
their parents. All procedures for collecting the human
samples were approved by the Provincial Ethics Com-
mittee of Santa Maria Nuova Hospital of Reggio Emilia.
hDPSCs were isolated from dental pulp, as previously
described by Riccio et al. [20]. The STRO-1+ hDPSCs
subpopulation of cells was obtained via magnetic-
activated cell sorting (MACS) (Miltenyi Biotec, Bergisch
Gladbach, Germany), using a mouse anti-STRO-1 anti-
body (Ab) (Santa Cruz Biotechnology, Inc., Dallas, TX,
USA).
Supernumerary amniocentesis samples were provided
by Laboratorio di Genetica, Ospedale Santa Maria Nuova
(Reggio Emilia, Italy). All the samples were collected
after informed consent was obtained from the patients
in accordance with Italian law and ethical committee
guidelines. hAFSCs were isolated as previously described
by De Coppi et al. [14]. Briefly, human amniocentesis cul-
tures were harvested by trypsinization and immunose-
lected by MACS by using a rabbit anti-c-Kit Ab (Santa
Cruz Biotechnology, Inc.). Both cell populations were ex-
panded in culture medium containing α-MEM (alpha-
minimum essential medium) plus 20 % fetal calf serum
(FCS), 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin (Sigma-Aldrich, St. Louis, MO,
USA) and incubated at 37 °C in an atmosphere of 5 %
CO2.
The expression of STRO-1 and c-Kit antigens was
assessed through immunofluorescent staining, as de-
scribed below. Moreover, the expression of STRO-1 and
c-Kit antigens by hDPSCs and hAFSCs, respectively, was
evaluated through fluorescence-activated cell sorting
(FACS) analysis by indirect staining using mouse anti-
STRO-1 IgM and rabbit anti-c-Kit IgG (Santa Cruz Bio-
technology, Inc.) followed by goat anti-mouse-IgG-
Alexa488 and goat anti-rabbit IgG-Alexa488 (Invitrogen,
part of Thermo Fisher Scientific, Waltham, MA, USA).
Non-specific fluorescence was assessed by using normal
mouse IgG or IgM followed by the secondary Ab as
described above. Samples were analyzed by using a 16-
parameter CyFlow ML flow cytometer (Partec GmbH,
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state, a 635-nm red diode laser, an ultraviolet mercury
lamp HBO, a 532-nm green solid-state laser, a 405-nm
violet laser, and a charge-coupled device camera. Data
were acquired in list mode by using FloMax (Partec
GmbH) software and then analyzed by FlowJo 9.4.11
(Treestar Inc., now part of FlowJo LLC, Ashland, OR,
USA) under MacOS 10.
Animals
Eight- to ten-week-old male B10ScSn.Cg-Prkdcscid
Dmdmdx/J (mdx/SCID; The Jackson Laboratory, Bar
Harbor, ME, USA) mice were housed in the animal facil-
ity located in the Bridgeside Point II building, University
of Pittsburgh, under stable conditions of humidity and
temperature in a controlled vivarium on a 12:12 h light-
dark cycle with free access to food and water. All of the
animal experiments were performed following approval
by the Institutional Animal Care and Use Committee
(IACUC) of the University of Pittsburgh.
Myogenic differentiation in vitro
To evaluate the myogenic potential of the STRO-1+
hDPSCs and c-Kit+ hAFSCs, the cells underwent distinct
differentiation protocols. The first protocol required the
direct co-culture of the hDPSCs or hAFSCs with the
C2C12 mouse myoblast cell line as previously described
by Pisciotta et al. [21]. Human stem cells and mouse
myoblasts were seeded on coverslips at a ratio of 10:1
and maintained in expansion medium containing DMEM
high glucose (DMEM-HG) plus 10 % FCS, 2 mM L-glu-
tamine, 100 U/ml penicillin, and 100 μg/ml streptomycin,
until the cells reached confluency. At this point, the ex-
pansion medium was replaced with fusion medium, con-
taining DMEM-HG plus 1 % FCS, 2 mM L-glutamine,
100 U/ml penicillin, 100 μg/ml streptomycin, and 10 nM
insulin and continued to be co-cultured in fusion medium
for 14 days.
The second protocol involved the myogenic differenti-
ation of hDPSCs and hAFSCs by first treating the cells
with 10 μM 5-Aza without direct co-culture. hDPSCs
and hAFSCs were seeded on coverslips at a cell density
of 4000 cells/cm2 in expansion medium (DMEM-HG
plus 10 % FCS, 2 mM L-glutamine, 100 U/ml penicillin,
and 100 μg/ml streptomycin), and upon reaching con-
fluency the medium was replaced with DMEM low glu-
cose (DMEM-LG), plus 10 % horse serum, 0.5 % chicken
serum, 2 mM L-glutamine, 100 U/ml penicillin, and
100 μg/ml streptomycin, supplemented with 10 μM 5-
Aza for 24 h. Subsequently, cells were rinsed twice in
phosphate-buffered saline (PBS) and kept in myogenic
medium containing DMEM-LG, plus 5 % horse serum,
0.5 % chicken serum, 2 mM L-glutamine, 100 U/ml
penicillin, 100 μg/ml streptomycin, and 10 nM insulinfor 24 h. The following day, the horse serum concentra-
tion in the myogenic medium was reduced to 2 %. Half
of the hDPSCs and hAFSCs were differentiated under
these conditions while the other half underwent the
same treatment with the addition of CM from differenti-
ated C2C12 mouse myoblast cells.
Western Blot
To further evaluate the in vitro differentiation capacities
of the STRO-1+ hDPSCs and c-Kit+ hAFSCs after their
induction toward a myogenic lineage using the protocols
outlined above, Western blot (WB) analysis was per-
formed. Whole cell lysates were obtained at 2 weeks after
initiating differentiation and processed as previously de-
scribed by Pisciotta et al. [21]. Thirty micrograms of
protein extract, quantified by a Bradford Protein Assay
(Bio-Rad Laboratories, Hercules, CA, USA), underwent
SDS-polyacrylamide gel electrophoresis and were trans-
ferred to PVDF membranes. The following Abs were
used: mouse anti-myogenin and rabbit anti-desmin
(Sigma-Aldrich), all diluted 1:1000. Peroxidase-labelled
anti-mouse (diluted 1:2000) and anti-rabbit (diluted
1:3000) secondary Abs were used. Whole cell lysate ob-
tained from C2C12 myoblasts was used as a positive
control. The membranes were visualized by using en-
hanced chemioluminescence (Amersham, now part of
GE Healthcare, Little Chalfont, UK). Anti-actin Ab was
used as control of protein loading. Densitometry of the
bands was performed by using ImageJ analysis software
(National Institutes of Health, Bethesda, MD, USA).
Data were then normalized to values of background and
the control actin band.
In vivo transplantation of the hDPSCs and hAFSCs into
mdx/SCID mice
To evaluate whether the hDPSCs and hAFSCs were cap-
able of contributing to the regeneration of dystrophin-
expressing myofibers, both human stem cell populations
demethylated with 10 μM 5-Aza and pre-differentiated
in vitro for 2 weeks in myogenic medium, with and
without the addition of CM from the differentiated
C2C12 cells, were transplanted into the gastrocnemius
muscles (GMs) of mdx/SCID mice. Briefly, pre-
differentiated hDPSCs and hAFSCs (5 × 105), re-
suspended in 30 μl of PBS, were injected into the GMs
of male mdx/SCID mice that were 8–10 weeks of age.
Each animal received two injections: in the left GM,
the cells pre-differentiated after demethylating treat-
ment; in the right GM, the cells pre-differentiated after
demethylating treatment and the addition of CM. Non-
injected muscles were used as negative controls. The
animals were euthanized at 7, 14, and 28 days after cell
transplantation, and the GMs were harvested and then
snap-frozen in liquid nitrogen-cooled 2-methylbutane.
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the frozen muscles were cut by using an H525
MICROM cryostat (Thermo Fisher Scientific). Sections
were collected on Super Frost Plus slides (Thermo
Fisher Scientific) and then stored at −80 °C. In total, 30
animals were used in this study (controls n = 6; treated
n = 24). Animal procedures were performed in compli-
ance with the guidelines approved by the IACUC of
the University of Pittsburgh (Pittsburgh, PA, USA).
Immunofluorescent microscopy and histology
hDPSCs and hAFSCs were seeded on coverslips follow-
ing MACS for STRO-1 and c-Kit, respectively. Once ad-
hered, the cells were fixed with 4 % paraformaldehyde,
blocked with 3 % bovine serum albumin (BSA) in PBS
for 30 min at room temperature, and incubated with
mouse anti-STRO-1 and rabbit anti-c-Kit primary Abs
(Santa Cruz Biotechnology, Inc.) diluted 1:50 in PBS
containing 3 % BSA for 1 h at room temperature. After
washing in PBS containing 3 % BSA, the samples were
incubated for 1 h at room temperature with the second-
ary Abs diluted 1:200 in PBS containing 3 % BSA (goat
anti-mouse Alexa546 and goat anti-rabbit Alexa488;
Invitrogen). After washing in PBS, samples were stained
with 1 μg/ml 4′,6-diamidino-2-phenylindole (DAPI) in
PBS for 1 min and then mounted with anti-fade medium
(VectaMount AQ Aqueous Mounting Medium; Vector
Laboratories, Burlingame, CA, USA). Negative controls
consisted of samples not incubated with the primary Ab.
Immunofluorescence analysis was performed by using a
Nikon A1 confocal laser scanning microscope (Nikon,
Tokyo, Japan) as described by Riccio et al. [20]. The con-
focal serial sections were processed with ImageJ software
to obtain three-dimensional projections, and image ren-
dering was performed by using Adobe Photoshop Soft-
ware (Adobe Systems Incorporated, San Jose, CA, USA).
Fixed monolayer cells, differentiated in vitro on cover-
slips, were permeabilized with 0.1 % Triton X-100 in
PBS for 5 min and then blocked with 3 % BSA in PBS
for 30 min at room temperature. The following primary
Abs were used: mouse anti-human nuclei (hNu) (EMD
Millipore, Billerica, MA, USA), mouse anti-myogenin,
rabbit anti-MyHC, and rabbit anti-desmin (all from
Sigma-Aldrich). All the primary Abs were diluted 1:50 in
PBS containing 3 % BSA and incubated for 1 h at room
temperature. Secondary Abs were diluted 1:200 in PBS
containing 3 % BSA and incubated for 1 h at room
temperature (goat anti-mouse Alexa488 and donkey
anti-rabbit Alexa594; Invitrogen); after washing in PBS,
the cells were counterstained with 1 μg/ml DAPI in PBS
for 3 min and then mounted with anti-fade medium
(VectaMount AQ Aqueous Mounting Medium; Vector
Laboratories). Negative controls consisted of samples
not incubated with the primary Ab.Histological unfixed sections from frozen muscle were
processed as described above. Mouse anti-human mito-
chondrial protein (hMit) (1:80; EMD Millipore), rabbit
anti-human dystrophin (1:500, kindly provided by Bing
Wang, University of Pittsburgh), and rabbit anti-human
von Willebrand factor (hvWill) (1:100; EMD Millipore)
were used as primary Abs. The following secondary Abs
were used at a 1:200 dilution: donkey anti-mouse Alexa488,
donkey anti-rabbit Alexa594, donkey anti-mouse Alexa594,
and goat anti-rabbit Alexa488 (Invitrogen). Samples not
incubated with primary Abs were used as negative con-
trols. Immunofluorescence analysis was performed on a
Nikon Eclipse E800 microscope (Nikon) by using Northern
Eclipse imaging software (EMPIX Imaging) to capture im-
ages. The image rendering was performed by using Adobe
Photoshop software.
Routine hematoxylin and eosin (H&E) staining was
performed on serial cross-sections (8 μm) of frozen
GMs in order to analyze the morphological details of the
tissues. Images of the entire muscle section were cap-
tured, the number of centrally nucleated myofibers was
determined, and the percentage of centrally nucleated fi-
bers to all myofibers in the entire muscle section was
calculated. Likewise, the average sizes of centrally nucle-
ated fibers and whole muscle fibers were measured.
The extent of fibrosis in the muscle cryosections was
determined by using Masson’s trichrome staining to de-
tect the collagen content of the muscles, as detailed in
the protocol of the manufacturer (Masson’s Trichrome
stain kit; IMEB, Inc., San Marcos, CA, USA). Images of
the histological samples were obtained with a Nikon
Eclipse E800 microscope.
The extent of angiogenesis in the injected muscle
cryosections was determined by quantifying the number
of blood vessels (vasa) positively stained by anti-hvWill
Ab. Values, calculated on three different cryosections of
each of the six samples per experimental group, were
expressed as mean ± standard deviation.
Statistical analysis
Data were expressed as the mean ± standard deviation.
Differences between experimental groups consisting of
5–6 samples each were analyzed by analysis-of-variance
test followed by Tukey’s Multiple Comparison Test
(GraphPad Prism Software version 5; GraphPad Soft-
ware, Inc., San Diego, CA, USA). In all analyses, P values
of less than 0.05 were considered statistically significant.
Results
Cell sorting
To verify whether hDPSCs and hAFSCs previously
sorted by MACS were STRO-1+ and c-Kit+, respectively,
immunocytochemistry and flow cytometry were per-
formed (Fig. 1a). Immunocytochemical analysis showed
Fig. 1 Cell characterization after cell sorting and evaluation of direct
co-culture with C2C12 mouse myoblasts. a Cell characterization after
MACS. On the top, fluorescent images of hDPSCs and hAFSCs positively
labeled with anti-STRO-1 (red) and anti-c-Kit (green) antibodies,
respectively. At the bottom, flow cytofluorimetric analysis of hDPSCs
and hAFSCs sorted by MACS; the percentage of positive cells is
indicated. b Evaluation of in vitro direct co-culture of hDPSCs and
hAFSCs with C2C12 mouse myoblasts. Triple immunofluorescent
staining of hAFSCs and hDPSCs co-cultured with C2C12 mouse
myoblasts revealed newly formed myotubes which are labeled with
DAPI (blue), anti-hNu (green), and anti-MyHC (red) antibodies. C2C12
cells differentiated alone were used as control. Scale bars = 50 μm. DAPI
4′,6-diamidino-2-phenylindole, hAFSC human amniotic fluid stem
cell, hDPSC human dental pulp stem cell, hNu human nuclei, MACS
magnetic-activated cell sorting, MyHC myosin heavy chain
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surface antigens (Fig. 1a, top). Moreover, flow cytometry
demonstrated that almost all of the sorted cells were
positive for STRO-1 and c-Kit, respectively (Fig. 1a,
bottom).
Myogenic differentiation in vitro
To test the cell populations’ myogenic potential, the
hDPSCs and hAFSCs were induced to differentiate into
a myogenic lineage in vitro. The immunofluorescent
analysis performed on the hDPSCs and hAFSCs after
14 days of direct co-culture with C2C12 cells revealed
the formation of myotubes that were positive for both
anti-hNu and anti-MyHC Abs, as shown in Fig. 1b (top).
In particular, newly formed hybrid myotubes that con-
tained both human and mouse nuclei were observed. As
expected, C2C12 cells differentiated alone did not show
any positive staining to anti-hNu Ab (Fig. 1b, bottom).
Immunofluorescent labeling was also carried out on
the hDPSCs and hAFSCs differentiated alone, following
DNA demethylation treatment with 5-Aza (Fig. 2). After
14 days of induction, the hDPSCs expressed myogenin,
which is an early marker for the entry of myoblasts into
the differentiation pathway; moreover, they expressed
MyHC and desmin, which are late-myogenic markers.
The hAFSCs also underwent myogenic commitment as
demonstrated by their positive staining for myogenin,
MyHC, and desmin, which confirmed the terminal myo-
genic commitment of the cells (Fig. 2a). Similar results
were observed for both the hDPSCs and hAFSCs differ-
entiated after demethylation with the addition of CM
from the differentiated C2C12 cell cultures (Fig. 2a).
After 2 weeks of induction, no myotube formation was
detected; however, after 4 weeks, myotube formation
could be detected in both the hDPSC and hAFSC cultures
(Fig. 2b). hDPSCs and hAFSCs cultured in myogenic in-
duction medium, but not undergoing preliminary demeth-
ylation treatment, did not show any labeling for the
Fig. 2 (See legend on next page.)
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Fig. 2 Immunofluorescent analysis after 2 and 4 weeks of myogenic differentiation of hDPSCs and hAFSCs by demethylation treatment.
Immunofluorescent staining with anti-myogenin (green)/anti-MyHC (red) and anti-myogenin (green)/anti-desmin (red) antibodies. Myogenic
differentiation was induced with and without the addition of CM from differentiated C2C12 cultures. Human DPSCs and AFSCs underwent myogenic
commitment as early as after 14 days of induction (a) by expressing the muscle-specific markers myogenin, MyHC, and desmin. However,
multinucleated myotube formation occurred only after 4 weeks of induction (b). Scale bars = 50 μm. CM conditioned medium, hAFSC human amniotic
fluid stem cell, hDPSC human dental pulp stem cell, MyHC myosin heavy chain
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(Additional file 1: Fig. S1).
To verify the commitment and differentiation of the
hDPSCs and hAFSCs toward a myogenic lineage, the ex-
pression of myogenin and desmin was also evaluated by
WB analysis by using whole cell lysates from the
hDPSCs and hAFSCs treated with 5-Aza and treated or
not treated with C2C12 CM (Fig. 3, top). A densitomet-
ric analysis was carried out on the WB bands to obtain a
semi-quantitative analysis of the protein amount (Fig. 3,
bottom). Both the hDPSCs and hAFSCs expressed the
muscle-specific markers myogenin and desmin after
2 weeks of myogenic induction as revealed by the exist-
ence of the specific protein bands corresponding to 34
and 50 kDa, respectively (Fig. 3). Densitometric analysis
revealed that, in both the differentiated hDPSCs and
hAFSCs, both with and without being treated with the
C2C12 CM, there was a significant expression of the myo-
genic markers compared with the controls (***P <0.001).
In particular, a significantly higher expression of both
myogenin- and desmin-positive cells were observed in the
hDPSC and hAFSC cultures differentiated via 5-Aza with
the addition of C2C12 CM than in the cultures not treated
with C2C12 CM, respectively (§§§P <0.001).
Engraftment evaluation and muscle regeneration after
in vivo transplantation
hDPSCs and hAFSCs that were pre-differentiated for
2 weeks toward a myogenic lineage, via 5-Aza demethyl-
ation, with and without treatment with C2C12 CM, were
injected into the GMs of mdx/SCID mice to test their
ability to regenerate dystrophin-expressing muscle fibers
within the dystrophic skeletal muscle of mdx/SCID mice.
The injected animals were sacrificed at different time
points, and the GMs were flash-frozen and processed for
further analyses. Immunofluorescent analysis showed
that as early as 7 days after injection the hDPSCs and
hAFSCs could be detected histologically within the host
muscle, as demonstrated by the positive staining of hu-
man mitochondrial protein. Similar results were ob-
served with or without culturing the cells in C2C12 CM
(Fig. 4). Double immunofluorescent staining, performed
7 days after cell injection by using anti-hMit and anti-
hvWill Abs, revealed the presence of human cells posi-
tively stained as endothelial cells within the blood vessel
walls (Fig. 5). Quantification of vasa positively stainedby anti-hvWill Ab did not show any significant differ-
ences between the experimental groups (Fig. 5, histo-
grams). Untreated samples, consisting of non-injected
GMs, did not show any positive staining against hMit
and hvWill Abs (Figs. 4 and 5). Moreover, 2 weeks after
cell injection, the immunofluorescent labelling showed
the presence of dystrophin-expressing myofibers within
the injected dystrophic skeletal muscle. In particular, the
myofibers expressing dystrophin were also positively
stained for human mitochondrial protein (Fig. 6). Similar
results were observed for both pre-differentiation condi-
tions (Fig. 6a). Restored expression of dystrophin by the
mouse muscle fibers positively labelled for anti-human
mitochondria Ab was still detectable 4 weeks after cell
injection (Fig. 6b). Again, similar results were observed
by using both pre-differentiation conditions (Fig. 6a, b).
The number of dystrophin-positive myofibers was very
limited after the injection of either hDPSCs and hAFSCs;
therefore, they could resemble revertant myofibers.
Histological and histomorphometric analyses
To evaluate the presence of fibrous tissue within the
dystrophic skeletal muscle of the mdx/SCID mice after
cell injection, serial sections from GMs harvested at
4 weeks after injection were stained with H&E and Mas-
son’s trichrome. Histological analysis of H&E staining re-
vealed that the muscles injected with human stem cells
contained areas of muscle regeneration, as demonstrated
by the presence of centronucleated muscle fibers
(Fig. 7a). Particularly, the percentages of centronucleated
muscle fibers in the GMs treated with hDPSCs and
hAFSCs were significantly higher when compared with
the non-injected (control) GM group (Fig. 7b, upper
left).
Similarly, analysis of Masson’s trichrome staining in
Fig. 7a shows a reduction in fibrosis within the skeletal
muscle injected with the pre-differentiated hDPSCs and
hAFSCs, compared with the controls. In particular, the
GMs treated with hDPSCs and hAFSCs showed a signifi-
cant reduction (P < 0.01) in fibrotic areas in comparison
with the non-injected (control) GMs (Fig. 7b, upper
right).
Moreover, histomorphometric analysis revealed that
the average sizes (in square micrometers) of centrally
nucleated fibers were significantly higher in GMs treated
with hDPSCs and hAFSCs compared with the non-
Fig. 3 (See legend on next page.)
Pisciotta et al. Stem Cell Research & Therapy  (2015) 6:156 Page 8 of 15
(See figure on previous page.)
Fig. 3 Western blot analysis of muscle-specific markers in differentiated hDPSCs and hAFSCs. Western blot analysis of myogenin and desmin
expression in whole cell lysates of differentiated hDPSCs and hAFSCs with (hDPSCs Aza + cm, hAFSCs Aza + cm) and without the addition of
C2C12 CM (hDPSCs Aza, hAFSCs Aza). Whole cell lysates were collected from three plates for each experimental group. Actin bands demonstrate
that an equal amount of protein was loaded in each lane. Densitometric analysis of Western blot bands is shown at the bottom (analysis of
variance followed by Tukey’s test: ***P < 0.001 hDPSCs Aza and hDPSCs Aza + cm versus undiff hDPSCs; ***P < 0.001 hAFSCs Aza and hAFSCs Aza + cm
versus undiff hAFSCs; §§§P < 0.001 hDPSCs Aza + cm versus hDPSCs Aza; §§§P < 0.001 hAFSCs Aza + cm versus hAFSCs Aza). CM conditioned medium,
hAFSC human amniotic fluid stem cell, hDPSC human dental pulp stem cell
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the average sizes of whole muscle fibers in GMs treated
with hDPSCs and hAFSCs were significantly higher
compared with the non-injected controls (Fig. 7b, lower
right).
Discussion
The muscular dystrophies are a diverse set of genetic
myopathies characterized by progressive muscle weak-
ness, atrophy, and the replacement of healthy myofibers
with fat and scar tissue [22, 23]. Several forms of these
diseases are caused by mutations in components of theFig. 4 Engraftment evaluation 7 days after cell injection in mdx/SCID GMs. Im
shows the presence of human DPSCs and AFSCs within the host dystrophic m
Untreated samples, consisting of non-injected mdx/SCID GMs, were used as n
cell, DAPI 4′,6-diamidino-2-phenylindole, hDPSC, human dental pulp stem celldystrophin-glycoprotein complex (DGC), which links
the actin cytoskeleton of the myofibers to the extracellu-
lar matrix and is a fundamental component required to
maintain the contractile structure of the skeletal muscle
[24, 25]. Mutations that cause disruptions in the compo-
nent proteins of the DGC lead to a series of different
myopathies, of which DMD is both the most severe and
the most common, affecting 1 in 3500 live male births.
Homologues of DMD have been identified in several an-
imals, such as the dy/dy mouse, the extensively studied
mdx mouse, the mdx/utrn−/− (dystrophin- and utrophin-
deficient) mouse, and the muscular dystrophic goldenmunofluorescent staining with DAPI (blue) and anti-hMit antibody (red)
uscle, after the cell injection, following both differentiation conditions.
egative controls. Scale bars = 50 μm. hAFSC, human amniotic fluid stem
, GM gastrocnemius muscle, hMit human mitochondrial protein
Fig. 5 Evaluation of angiogenesis promotion 7 days after cell injection into mdx/SCID GMs. Immunofluorescent labeling with DAPI (blue),
anti-hvWill (green), and anti-hMit (red) antibodies. Green and red signals appear co-localized, showing that hDPSCs and hAFSCs are present within
the endothelium of new vasa. The number of vessels positive for hvWill, calculated on three different cryosections of the six samples per experimental
group, is expressed as mean ± standard deviation. Untreated samples, consisting of non-injected mdx/SCID GMs, were used as negative controls. Scale
bars = 50 μm. DAPI 4′,6-diamidino-2-phenylindole, GM gastrocnemius muscle, hAFSC human amniotic fluid stem cell, hDPSC human dental pulp stem
cell, hMit human mitochondrial protein, hvWill human von Willebrand factor
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of DMD at this time, the variety of DMD homologues
available is adequate for understanding the fundamental
pathophysiology of the disease [26].
Satellite cells (SCs) can keep up with muscle fiber loss
in the early stages of DMD because they can regenerate
the degenerated muscle fibers, and this leads to a mild
dystrophic phenotype. However, as previously demon-
strated by different research groups, the pool of SCs be-
comes exhausted as a result of high demands for muscle
regeneration and poor compensatory mechanisms, and
this results in fibrous and fatty connective tissue infiltra-
tion and then in muscle weakness [27–29].
Cell therapy has been considered as a potential thera-
peutic treatment for DMD over the years. Partridge
et al. [30] originally demonstrated that donor myoblasts
could fuse with each other or host myoblasts, suggestingthe possibility of functional restoration of dystrophin in
defective muscle fibers.
The pivotal findings that donor heterologous myoblasts
could restore dystrophin expression in the dystrophin-
deficient mdx mouse [31] laid the foundation for a
number of human clinical trials in DMD patients in the
1990s [32]. Initial clinical trials with allogeneic myoblast
injection into the muscles of non-immunosuppressed
DMD patients showed only a transient restoration of
dystrophin-positive fibers and limited improvements in
muscle strength because of a rapid cell death and im-
mune rejection of the injected cells [33–38]. The limita-
tions of these therapeutic approaches have triggered
extensive research over the years. One of the approaches
attempted the transplantation of bone marrow mesen-
chymal stem cells (MSCs) into the dystrophic muscles
of mdx mice which showed that the MSCs indeed
Fig. 6 (See legend on next page.)
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Fig. 6 Evaluation of dystrophin expression after cell injection in mdx/SCID GMs. a Immunofluorescent staining with DAPI (blue), anti-hMit (green),
and anti-hDystrophin (red) antibodies shows the presence of human DPSCs and AFSCs within human dystrophin-positive muscle fibers 14 days
after cell injection. b Dystrophin-expressing muscle fibers were also observed at 28 days post-injection. Untreated samples, consisting of
non-injected mdx/SCID GMs, were used as negative controls. Scale bars = 50 μm. hAFSC, human amniotic fluid stem cell, DAPI 4′,6-diamidino-2-pheny-
lindole, hDPSC, human dental pulp stem cell, GM gastrocnemius muscle, hDystrophin human Dystrophin
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into muscle tissue [7, 39, 40]. Besides bone marrow
MSCs, several cell types have been identified as poten-
tial sources for muscle tissue regeneration [41–44].
In the present study, we evaluated the myogenic po-
tential of STRO-1+-enriched hDPSCs and c-Kit
+-enriched hAFSCs. It has been well demonstrated that,
in the dental pulp, STRO-1+ stem cells are capable of
differentiating toward multilineage cell types with re-
spect to non-sorted cells and this is likely due to their
more homogeneous nature [45]. Similarly, as described
by De Coppi et al. [14] and Bai et al. [46], c-Kit+ cells
represent a group of purified MSCs newly found in am-
niotic fluid that have broad multipotency capacity.
Via two different protocols, this study aimed to deter-
mine the optimal conditions for achieving the myogenic
commitment of these two populations of human stem
cells. The results from the direct co-culture of hDPSCs
and hAFSCs with C2C12 mouse myoblasts demon-
strated that these human stem cells were capable of fus-
ing with mouse myoblasts to form hybrid myotubes, as
shown by the hNu in the myotubes through the use of
anti-hNu Ab.
After being differentiated without direct co-culture by
means of DNA demethylation treatment, immunofluor-
escence analysis revealed that hDPSCs and hAFSCs
underwent myogenic commitment, even though multi-
nucleated myotubes were not observed. Similarly, when
CM from differentiated C2C12 cells was added to the
myogenic medium of the demethylated cells, the expres-
sion of muscle-specific markers by the hDPSCs and
hAFSCs was observed. In particular, both hDPSCs and
hAFSCs reached myogenic commitment after 14 days of
induction as confirmed by the cells’ expression of
muscle-specific markers. Although myotube formation
was not observed at the 2-week time point, by 4 weeks
after the initiation of myogenic induction, myotubes
were detectable, with and without the addition of C2C12
CM. This further demonstrates the ability of the hDPSCs
and hAFSCs to undergo myogenic differentiation. The
induction of both hDPSCs and hAFSCs toward a myo-
genic lineage was further demonstrated by WB analysis
which showed that when CM from C2C12 cells was
added to the hDPSC and hAFSC cultures, the cells’ ex-
pression of myogenic-specific markers became more
pronounced. On the other hand, neither early nor late
myogenic differentiation markers could be detected inthe hDPSCs or hAFSCs when they were cultured in dif-
ferentiation medium without the demethylating process.
These observations suggest that modulating the myo-
genic potential of these populations of cells could be
achieved by combining demethylation (which triggers
the expression of muscle regulatory factors necessary for
the myogenic process to proceed) with the addition of
the C2C12 conditioned fusion media, which contains
soluble factors that promote myogenesis.
According to the results obtained in vitro, condition-
ing the cells with 5-Aza was found to be important for
triggering the myogenic commitment of the hDPSCs
and hAFSCs when differentiating the cells in the absence
of C2C12 cells; therefore, The demethylation treatment
of hDPSCs and hAFSCs with 5-Aza was performed as
part of the differentiation strategy to evaluate their myo-
genic potential in vivo when injected into the dystrophic
GMs of mdx/SCID mice.
Early engraftment was observed within the skeletal
muscle fibers of the host, as confirmed by the presence
of human cells in the injected muscles detected by stain-
ing for human mitochondria, which demonstrated that
some of these injected cells were able to survive and in-
tegrate into the host muscle after transplantation. In par-
ticular, hDPSCs and hAFSCs showed that they were
capable of supporting the improvement of skeletal
muscle by promoting neo-angiogenesis within the trans-
planted muscles, which is a key player in achieving good
physiological repair of the tissue [47]. In fact, according
to Biscetti et al., dystrophin expression is not limited to
skeletal muscle cells but is also expressed by several
other cell types, including endothelial cells [48], which
are known to interact directly and indirectly with myo-
blasts and promote the proliferation of myogenic precur-
sor cells [49]. The physiological importance of
dystrophin in the vascular endothelium is demonstrated
by the fact that mdx mice display vascular abnormalities
and their muscles experience ischemic conditions [50].
Recent findings showed that increasing the vasculature
in patients with DMD might be capable of ameliorating
the histological and functional phenotypes related to the
disease and that developing an efficacious therapy for
DMD would address improving both skeletal muscle re-
generation and its vasculature [51]. Double-positive
staining for human mitochondria and human von Will-
ebrand factor demonstrated that both the hDPSCs and
hAFSCs could be localized in the endothelium of newly
Fig. 7 Histological analyses of the injected and non-injected mdx/
SCID skeletal muscles. a H&E staining shows active muscle regeneration
within the muscles treated with human DPSCs and AFSCs, as
represented by a high number of centronucleated muscle fibers.
Comparison of fibrotic processes between controls (non-injected
mdx/SCID GMs) and mdx/SCID GMs injected with human DPSCs and
AFSCs. Masson’s trichrome staining indicates a reduction in fibrosis
within the muscles treated with human DPSCs and AFSCs, when
compared with controls (non-injected muscle). Scale bar = 50 μm.
b Histomorphometric analysis of the muscles treated with human
DPSCs and AFSCs. Upper left: histograms represent the percentage
of regenerating centronucleated muscle fibers. **P <0.01 versus
control (ANOVA followed by Tukey’s test). Upper right: histograms
represent the percentage area of fibrosis. **P <0.01 versus control
(ANOVA followed by Tukey’s test). Lower left: histograms represent
the average size (in square micrometers) of centrally nucleated muscle
fibers. ***P <0.001 versus control (ANOVA followed by Tukey’s test).
Lower right: histograms represent average size (in square micrometers)
of whole muscle fibers. ***P <0.001 versus control (ANOVA followed
by Tukey’s test). hAFSC, human amniotic fluid stem cell, ANOVA
analysis of variance, hDPSC, human dental pulp stem cell, GM
gastrocnemius muscle, H&E hematoxylin and eosin
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ports the fact that they participated in the neo-
angiogenesis of the transplanted muscle, a well-defined
property of the cells that has been previously shown
[6, 52, 53]. The ability of the hDPSCs and hAFSCs to
regenerate dystrophin-expressing myofibers within
the injected host muscles observed as early as 14 days
post-injection was minimal and within the threshold
of revertant myofibers (less than 1 %). Although these
muscle fibers were stained by an Ab that specifically de-
tects human dystrophin, which consequently indicated the
participation of donor cells in the regeneration process,
the number of human dystrophin-positive fibers was very
limited and similar to revertant muscle fibers.
Moreover, another important finding of the present
study was that the hDPSCs and hAFSCs contributed to
a reduction in the formation of fibrosis within the dys-
trophic muscle, which further enhanced the regeneration
process as was demonstrated by the increased number
of centronucleated muscle fibers. In particular, the
higher average sizes of centronucleated muscle fibers in
GMs treated with hDPSCs and hAFSCs in comparison
with control non-injected GMs suggest that the matur-
ation process of the regenerated muscle fibers is more
advanced in the cell-injected skeletal muscles.
These observations suggest that, once engrafted within
the host muscle, hDPSCs and hAFSCs actively contrib-
uted to the amelioration of the dystrophic phenotype
within the muscle by promoting angiogenesis and by re-
ducing the deposition of fibrosis. It is important to note
that muscle function was not tested in the present study,
because mdx mice, despite being used as a genetic
model of DMD, exhibit a very mild phenotype (especially
at young age) in terms of muscle weakness as compared
Pisciotta et al. Stem Cell Research & Therapy  (2015) 6:156 Page 14 of 15with patients with DMD [30]. The limited presence of
dystrophin-positive fibers observed after cell transplant-
ation could be attributable in part to limitations associ-
ated with xenotransplantation. Although the recipient is
a SCID mouse, the inflammatory process can still limit
the human stem cells to engraft and to functionally inte-
grate in the host tissue. In addition, it has been observed
that human stem cells exert, in general, a reduced ability
to fuse with murine myofibers [54, 55].
Conclusions
In light of these results, hDPSCs and hAFSCs hold
promise as two potential stem cell populations that
could be useful for the improvement of pathological fea-
tures of dystrophic skeletal muscle tissues, including the
reduction of fibrosis and the enhancement of angiogen-
esis in patients with DMD. These findings are aimed at
paving the way for further investigations in order to op-
timally characterize the contributions of hDPSCs and
hAFSCs to improve muscle function in DMD animal
models.
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Abbreviations
5-Aza: 5-Aza-2′-deoxycytidine; Ab: Antibody; BSA: Bovine serum albumin;
CM: Conditioned medium; DAPI: 4′,6-diamidino-2-phenylindole;
DGC: Dystrophin-glycoprotein complex; DMD: Duchenne muscular
dystrophy; DMEM-HG: Dulbecco’s modified Eagle’s medium-high glucose;
DMEM-LG: Dulbecco’s modified Eagle’s medium-low glucose; FCS: Foetal calf
serum; GM: Gastrocnemius muscle; H&E: Hematoxylin and eosin;
hAFSC: Human amniotic fluid stem cell; hDPSC: Human dental pulp stem
cell; hMit: Human mitochondrial protein; hNu: Human Nuclei; hvWill: Human
von Willebrand factor; IACUC: Institutional Animal Care and Use Committee;
MACS: Magnetic-activated cell sorting; MSC: Mesenchymal stem cell;
MyHC: Myosin heavy chain; PBS: Phosphate-buffered saline; SC: Satellite cell;
WB: Western blot.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AP designed and performed most of the experiments in vitro and in vivo,
collected and analyzed data, and drafted the manuscript. MR carried out
differentiation experiments and assays in vitro, collected and analyzed the
data, and drafted the manuscript. GC assisted with image analysis and data
collection, analysis and interpretation and drafted the manuscript. AL
provided assistance with in vivo experiments and data analysis and
interpretation and revised the manuscript. SDB and LG performed
supplemental experiments, collected and analyzed data, and assisted with
the revision of the manuscript. GBLS and GB provided collection of human
amniotic fluid and dental pulp samples, assisted with data analysis,
performed statistical analysis, and revised the manuscript. AF assisted with
analysis and interpretation of data from in vivo experiments and revised the
manuscript. JH and ADP supervised the experimental design, assisted with
data analysis, and drafted the manuscript. All authors read and approved the
final manuscript.Acknowledgements
The authors thank Gianfranco Croci (Laboratorio di Genetica, Ospedale Santa
Maria Nuova, Reggio Emilia, Italy) for providing sample of amniotic fluid cells
and James H. Cummins for his editorial assistance. This work was supported
by grants from ‘Progetto Strategico per lo sviluppo nella sede di Reggio
Emilia della Facoltà di Medicina e Chirurgia‘ (protocol 2010 0007725),
Arcispedale S. Maria Nuova di Reggio Emilia and MIUR FIRB Accordi di
Programma 2010 (protocol RBAP10Z7FS).
Author details
1Department of Surgical, Medical, Dental and Morphological Sciences with
interest in Transplant, Oncology and Regenerative Medicine, University of
Modena and Reggio Emilia, via del Pozzo 71, 41124 Modena, Italy. 2Stem Cell
Research Center, Department of Orthopaedic Surgery, University of
Pittsburgh, 450 Technology Drive, Bridgeside Point II, Suite 206, 15219
Pittsburgh, PA, USA. 3Department of Obstetrics and Gynecology, Arcispedale
Santa Maria Nuova, viale Risorgimento 80, 42123 Reggio Emilia, Italy.
4Oro-Maxillo-Facial Department, AUSL Baggiovara, via Giardini 1355, 41126
Modena, Baggiovara, Italy. 5Department of Biomedical, Metabolic and
Neuroscience, University of Modena and Reggio Emilia, Children
Rehabilitation Special Unit, IRCCS Arcispedale Santa Maria Nuova, viale
Risorgimento 80, 42123 Reggio Emilia, Italy.
Received: 24 December 2014 Revised: 7 May 2015
Accepted: 30 July 2015
References
1. Matsumura K, Ohlendieck K, Ionasescu VV, Tomé FM, Nonaka I, Burghes AH,
et al. The role of the dystrophin-glycoprotein complex in the molecular
pathogenesis of muscular dystrophies. Neuromuscul Disord. 1993;3:533–5.
2. Emery AE, Muntoni F. Duchenne Muscular Dystrophy. 3rd ed. Oxford, UK:
Oxford University Press; 2003.
3. Manzur AY, Kuntzer T, Pike M, Swan A. Glucocorticoid corticosteroids for
Duchenne muscular dystrophy. Cochrane Database Syst Rev.
2008;1:CD003725.
4. Drowley L, Okada M, Beckman S, Vella J, Keller B, Tobita K, et al. Cellular
antioxidant levels influence muscle stem cell therapy. Mol Ther.
2010;18:1865–73.
5. Gharaibeh B, Lavasani M, Cummins JH, Huard J. Terminal differentiation is
not a major determinant for the success of stem cell therapy - cross-talk
between muscle-derived stem cells and host cells. Stem Cell Res Ther.
2011;2:31.
6. Deasy BM, Feduska JM, Payne TR, Li Y, Ambrosio F, Huard J. Effect of VEGF
on the regenerative capacity of muscle stem cells in dystrophic skeletal
muscle. Mol Ther. 2009;17:1788–98.
7. Ferrari G, Cusella-De Angelis G, Coletta M, Paolucci E, Stornaiuolo A, Cossu
G, et al. Muscle regeneration by bone marrow-derived myogenic
progenitors. Science. 1998;281:923.
8. Pinheiro CH, de Queiroz JC, Guimarães-Ferreira L, Vitzel KF, Nachbar RT, de
Sousa LG, et al. Local injections of adipose-derived mesenchymal stem cells
modulate inflammation and increase angiogenesis ameliorating the
dystrophic phenotype in dystrophin-deficient skeletal muscle. Stem Cell Rev.
2012;8:363–74.
9. Brzóska E, Grabowska I, Hoser G, Stremińska W, Wasilewska D, Machaj EK,
et al. Participation of stem cells from human cord blood in skeletal muscle
regeneration of SCID mice. Exp Hematol. 2006;34:1262–70.
10. Kawamichi Y, Cui CH, Toyoda M, Makino H, Horie A, Takahashi Y, et al. Cells
of extraembryonic mesodermal origin confer human dystrophin in the mdx
model of Duchenne muscular dystrophy. J Cell Physiol. 2010;223:695–702.
11. Gronthos S, Mankani M, Brahim J, Robey PG, Shi S. Postnatal human dental
pulp stem cells (DPSCs) in vitro and in vivo. Proc Natl Acad Sci USA.
2000;97:13625–30.
12. Gronthos S, Brahim J, Li W, Fisher LW, Cherman N, Boyde A, et al. Stem cell
properties of human dental pulp stem cells. J Dent Res. 2002;81:531–5.
13. Pisciotta A, Carnevale G, Meloni S, Riccio M, De Biasi S, Gibellini L, et al.
Human Dental pulp stem cells (hDPSCs): isolation, enrichment and
comparative differentiation of two sub-populations. BMC Dev Biol.
2015;15:14.
14. De Coppi P, Bartsch Jr G, Siddiqui MM, Xu T, Santos CC, Perin L, et al.
Isolation of amniotic stem cell lines with potential for therapy. Nat
Biotechnol. 2007;25:100–6.
Pisciotta et al. Stem Cell Research & Therapy  (2015) 6:156 Page 15 of 1515. Carnevale G, Riccio M, Pisciotta A, Beretti F, Maraldi T, Zavatti M, et al. In
vitro differentiation into insulin-producing β-cells of stem cells isolated from
human amniotic fluid and dental pulp. Dig Liver Dis. 2013;45:669–76.
16. Duan C, Ren H, Gao S. Insulin-like growth factors (IGFs), IGF receptors, and
IGF-binding proteins: roles in skeletal muscle growth and differentiation.
Gen Comp Endocrinol. 2010;167:344–51.
17. Ye NS, Chen J, Luo GA, Zhang RL, Zhao YF, Wang YM. Proteomic profiling
of rat bone marrow mesenchymal stem cells induced by 5-azacytidine.
Stem Cells Dev. 2006;15:665–76.
18. Antonitsis P, Ioannidou-Papagiannaki E, Kaidoglou A, Charokopos N,
Kalogeridis A, Kouzi-Koliakou K, et al. Cardiomyogenic potential of human
adult bone marrow mesenchymal stem cells in vitro. Thorac Cardiovasc
Surg. 2008;56:77–82.
19. Montesano A, Luzi L, Senesi P, Terruzzi I. Modulation of cell cycle
progression by 5-azacytidine is associated with early myogenesis induction
in murine myoblasts. Int J Biol Sci. 2013;9:391–402.
20. Riccio M, Resca E, Maraldi T, Pisciotta A, Ferrari A, Bruzzesi G, et al. Human
dental pulp stem cells produce mineralized matrix in 2D and 3D cultures.
Eur J Histochem. 2010;54:e46.
21. Pisciotta A, Riccio M, Carnevale G, Beretti F, Gibellini L, Maraldi T, et al.
Human serum promotes osteogenic differentiation of human dental pulp
stem cells in vitro and in vivo. PLoS One. 2012;7:e50542.
22. Bushby K. Genetics and the muscular dystrophies. Dev Med Child Neurol.
2000;42:780–4.
23. Burton EA, Davies KE. Muscular dystrophy - reason for optimism? Cell.
2002;108:5–8.
24. Watkins SC, Swartz DR, Byers TJ. Localisation of dystrophin in skeletal,
cardiac and smooth muscle. In Dystrophin: Gene, Protein and Cell Biology.
Edited by Brown SC and Lucy JA. Cambridge, United Kingdom: University
Press, Cambridge; 1997:79–104.
25. Michele DE, Campbell KP. Dystrophin-glycoprotein complex:
post-translational processing and dystroglycan function. J Biol Chem.
2003;278:15457–60.
26. Collins CA, Morgan JE. Duchenne’s muscular dystrophy: animal models used
to investigate pathogenesis and develop therapeutic strategies. Int J Exp
Pathol. 2003;84:165–72.
27. Miller JB, Schaefer L, Dominov JA. Seeking muscle stem cells. Curr Top Dev
Biol. 1999;43:191–219.
28. Lund TC, Grange RW, Lowe DA. Telomere shortening in diaphragm and
tibialis anterior muscles of aged mdx mice. Muscle Nerve. 2007;36:387–90.
29. Lu A, Poddar M, Tang Y, Proto JD, Sohn J, Mu X, et al. Rapid depletion of
muscle progenitor cells in dystrophic mdx/utrophin−/− mice. Hum Mol
Genet. 2014;23:4786–800.
30. Partridge TA, Grounds M, Sloper JC. Evidence of fusion between host and
donor myoblasts in skeletal muscle grafts. Nature. 1978;273:306–8.
31. Partridge TA, Morgan JE, Coulton GR, Hoffman EP, Kunkel LM. Conversion of
mdx myofibres from dystrophin-negative to -positive by injection of normal
myoblasts. Nature. 1989;337:176–9.
32. Partridge TA. The current status of myoblast transfer. Neurol Sci.
2000;21:S939–942.
33. Law PK. Beneficial effects of transplanting normal limb-bud mesenchyme
into dystrophic mouse muscles. Muscle Nerve. 1982;5:619–27.
34. Huard J, Bouchard JP, Roy R, Malouin F, Dansereau G, Labrecque C, et al.
Human myoblast transplantation: preliminary results of 4 cases. Muscle
Nerve. 1992;15:550–60.
35. Karpati G, Ajdukovic D, Arnold D, Gledhill RB, Guttmann R, Holland P, et al.
Myoblast transfer in Duchenne muscular dystrophy. Ann Neurol.
1993;34:8–17.
36. Mendell JR, Kissel JT, Amato AA, King W, Signore L, Prior TW, et al. Myoblast
transfer in the treatment of Duchenne’s muscular dystrophy. N Engl J Med.
1995;333:832–8.
37. Gussoni E, Pavlath GK, Lanctot AM, Sharma KR, Miller RG, Steinman L, et al.
Normal dystrophin transcripts detected in Duchenne muscular dystrophy
patients after myoblast transplantation. Nature. 1992;356:435–8.
38. Beauchamp JR, Pagel CN, Partridge TA. A dual-marker system for
quantitative studies of myoblast transplantation in the mouse.
Transplantation. 1997;63:1794–7.
39. Saito T, Dennis JE, Lennon DP, Young RG, Caplan AI. Myogenic expression
of Mesenchymal Stem Cells within myotubes of mdx mice in vitro and
in vivo. Tissue Eng. 1995;1:327–43.40. Gussoni E, Soneoka Y, Strickland CD, Buzney EA, Khan MK, Flint AF, et al.
Dystrophin expression in the mdx mouse restored by stem cell
transplantation. Nature. 1999;401:390–4.
41. Torrente Y, Belicchi M, Sampaolesi M, Pisati F, Meregalli M, D’Antona G, et al.
Human circulating AC133(+) stem cells restore dystrophin expression and
ameliorate function in dystrophic skeletal muscle. J Clin Invest.
2004;114:182–95.
42. Huard J, Cao B, Qu-Petersen Z. Muscle-derived stem cells: potential for
muscle regeneration. Birth Defects Res C Embryo Today. 2003;69:230–7.
43. Mitchell KJ, Pannérec A, Cadot B, Parlakian A, Besson V, Gomes ER, et al.
Identification and characterization of a non-satellite cell muscle resident
progenitor during postnatal development. Nat Cell Biol. 2010;12:257–66.
44. Sampaolesi M, Torrente Y, Innocenzi A, Tonlorenzi R, D’Antona G, Pellegrino
MA, et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through
intra-arterial delivery of mesoangioblasts. Science. 2003;25:487–92.
45. Yang X, Zhang W, van den Dolder J, Walboomers XF, Bian Z, Fan M, et al.
Multilineage potential of STRO-1+ rat dental pulp cells in vitro. Tissue Eng
Regen Med. 2007;1:128–35.
46. Bai J, Wang Y, Liu L, Chen J, Yang W, Gao L, et al. Human amniotic
fluid-derived c-Kit(+) and c-Kit (−) stem cells: growth characteristics and
some differentiation potential capacities comparison. Cytotechnology.
2012;64:577–89.
47. Auger FA, Gibot L, Lacroix D. The pivotal role of vascularization in tissue
engineering. Annu Rev Biomed Eng. 2013;15:177–200.
48. Biscetti F, Gaetani E, Flex A, Aprahamian T, Hopkins T, Straface G, et al.
Selective activation of peroxisome proliferator activated receptor (PPAR)
alpha and PPAR gamma induces neoangiogenesis through a vascular
endothelial growth factor-dependent mechanism. Diabetes.
2008;57:1394–404.
49. Sabourin LA, Girgis-Gabardo A, Seale P, Asakura A, Rudnicki MA. Reduced
differentiation potential of primary MyoD−/− myogenic cells derived from
adult skeletal muscle. J Cell Biol. 1999;144:631–43.
50. Shimizu-Motohashi Y, Asakura A. Angiogenesis as a novel therapeutic
strategy for Duchenne muscular dystrophy through decreased ischemia and
increased satellite cells. Front Physiol. 2014;5:50.
51. Palladino M, Gatto I, Neri V, Straino S, Smith RC, Silver M, et al. Angiogenic
impairment of the vascular endothelium: a novel mechanism and potential
therapeutic target in muscular dystrophy. Arterioscler Thromb Vasc Biol.
2013;33:2867–76.
52. Hilkens P, Fanton Y, Martens W, Gervois P, Struys T, Politis C, et al.
Pro-angiogenic impact of dental stem cells in vitro and in vivo. Stem Cell
Res. 2014;12:778–90.
53. Liu YW, Roan JN, Wang SP, Hwang SM, Tsai MS, Chen JH, et al. Xenografted
human amniotic fluid-derived stem cell as a cell source in therapeutic
angiogenesis. Int J Cardiol. 2013;168:66–75.
54. Chirieleison SM, Feduska JM, Schugar RC, Askew Y, Deasy BM. Human
muscle-derived cell populations isolated by differential adhesion rates:
phenotype and contribution to skeletal muscle regeneration in Mdx/SCID
mice. Tissue Eng Part A. 2011;18:232–41.
55. Meng J, Adkin CF, Xu SW, Muntoni F, Morgan JE. Contribution of human
muscle-derived cells to skeletal muscle regeneration in dystrophic host
mice. PLoS One. 2011;6:e17454.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
